Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03486704
Other study ID # VR-Rehab-MCI
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date April 9, 2018
Est. completion date June 30, 2024

Study information

Verified date March 2024
Source IRCCS Centro San Giovanni di Dio Fatebenefratelli
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The main aim of the study is to evaluate the efficacy of the Virtual Reality Rehabilitation System (VRRS) compared to usual care treatment for patients with Mild Cognitive Impairment (MCI). Moreover, we will assess the possibility to prolong the beneficial effects of the treatment with an innovative telerehabilitation system. In the second phase of the present study we aim to evaluate the short and long term effects induced by the treatment of active (anodal) transcranial Direct Current Stimulation (tDCS) applied to the left dorsolateral prefrontal cortex combined with VRRS compared to placebo tDCS stimulation combined with VRRS. The effects of the intervention on outcome variables will be assessed using a randomized controlled trial design with five groups. The investigators will assess the effects of VRRS system and of the implementation of the at-home treatment on the quality of life, cognitive and functional abilities.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 109
Est. completion date June 30, 2024
Est. primary completion date June 30, 2024
Accepts healthy volunteers No
Gender All
Age group 60 Years to 85 Years
Eligibility Inclusion Criteria: - Diagnosis of MCI, defined according to standard criteria (Petersen et al., 2011) - Mini Mental State Examination (MMSE) =24 - Education = 5 years - All of the subjects will have normal or corrected-to-normal vision and will be native Italian speakers. - All participants reported subjective memory complaints and objective memory impairment, but no impairment of function in daily life. Exclusion Criteria: - visual perception disorder and/or hearing loss - history of major psychiatric disorders - any contraindication for tDCS such as a history of seizures, major head trauma, past brain surgery, a brain metal implant or a pacemaker.

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Face to Face VRRS and telerehabilitation
Face to Face cognitive training using VRRS plus telerehabilitation. Participants will receive 12 sessions of an individualized Face to Face cognitive training using VRRS over 4 weeks followed by 36 sessions of home-based VRRS cognitive training, three sessions for week. Cognitive training will initially be tailored to the patient's baseline characteristics. The exercise program will be charged by therapist on the patient's computer before the beginning of the at-home treatment. Each patient's performed session will be reviewed by the therapist. The group will receive a kit home-based (a tablet home, access to a daily individualized cognitive training program).
Usual rehabilitation program
The usual rehabilitation group will receive 12 sessions of face-to-face usual cognitive training program.
FTF VRRS plus unstructured CS
Face to Face cognitive training using VRRS plus at-home unstructured cognitive stimulation. Participants will receive 12 sessions of an individualized Face to Face (FTF) cognitive training using VRRS over 4 weeks followed by 36 sessions of home-based unstructured cognitive stimulation (CS), three sessions for week.
Face to Face VRRS plus active tDCS and telerehabilitation
Participants will receive 12 sessions of an individualized Face to Face cognitive training using VRRS combined with active (anodal) tDCS applied to the left dorsolateral prefrontal cortex over 4 weeks followed by 36 sessions of home-based VRRS cognitive training, three sessions for week. Face to Face VRRS cognitive training will initially be tailored to the patient's baseline characteristics. The exercise program will be charged by therapist on the patient's computer before the beginning of the at-home treatment. Each patient's performed session will be reviewed by the therapist.The group will receive a kit home-based (a tablet home, access to a daily individualized cognitive training program).
Face to Face VRRS plus placebo tDCS and telerehabilitation
Participants will receive 12 sessions of an individualized Face to Face cognitive training using VRRS combined with placebo tDCS applied to the dorsolateral prefrontal cortex of the left hemisphere over 4 weeks followed by 36 sessions of home-based VRRS cognitive training, three sessions for week. Face to Face VRRS cognitive training will initially be tailored to the patient's baseline characteristics. The exercise program will be charged by therapist on the patient's computer before the beginning of the at-home treatment. Each patient's performed session will be reviewed by the therapist.The group will receive a kit home-based (a tablet home, access to a daily individualized cognitive training program).

Locations

Country Name City State
Italy IRCCS Centro san Giovanni di Dio Brescia BS

Sponsors (4)

Lead Sponsor Collaborator
IRCCS Centro San Giovanni di Dio Fatebenefratelli Fondazione Don Carlo Gnocchi Onlus, IRCCS Centro Neurolesi Bonino-Pulejo, Messina (IT), IRCCS San Raffaele

Country where clinical trial is conducted

Italy, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in long term episodic verbal memory Free and Cued Selective Reminding Test (FCSRT) Baseline up to 12 weeks and 4 and 7 months
Primary Change in long term episodic verbal memory Auditory Verbal Learning Test, immediate and delayed recall Baseline up to 12 weeks and 4 and 7 months
Secondary Change in measure of quality of life Quality of Life in Alzheimer's Disease (AD) - QoL-AD Baseline up to 12 weeks and 4 and 7 months
Secondary Change in dementia severity Clinical Dementia Rating scale (CDR) Baseline up to 12 weeks and 4 and 7 months
Secondary Change in global cognition Mini Mental State Examination (MMSE) Baseline up to 12 weeks and 4 and 7 months
Secondary Change in memory complaints Everyday Memory Questionnaire (EMQ) Baseline up to 12 weeks and 4 and 7 months
Secondary Change in visual constructional abilities Rey-Osterrieth Figure Copy Baseline up to 12 weeks and 4 and 7 months
Secondary Change in nonverbal long term memory Rey-Osterrieth Figure Recall Baseline up to 12 weeks and 4 and 7 months
Secondary Change in visual attention and task switching Trail Making Test Baseline up to 12 weeks and 4 and 7 months
Secondary Change in naming abilities Object and action naming subtests of the Battery for the Analysis of the Aphasic Deficit Baseline up to 12 weeks and 4 and 7 months
Secondary Change in non-verbal abstract reasoning Raven's Colored Progressive Matrices Baseline up to 12 weeks and 4 and 7 months
Secondary Change in verbal fluency Phonemic verbal fluency and semantic verbal fluency Baseline up to 12 weeks and 4 and 7 months
See also
  Status Clinical Trial Phase
Completed NCT04513106 - Promoting Advance Care Planning for Persons With Early-stage Dementia in the Community: a Feasibility Trial N/A
Recruiting NCT06011681 - The Rapid Diagnosis of MCI and Depression in Patients Ages 60 and Over
Recruiting NCT04522739 - Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early Alzheimer's Disease Phase 4
Active, not recruiting NCT03167840 - Falls Prevention Through Physical And Cognitive Training in Mild Cognitive Impairment N/A
Active, not recruiting NCT03676881 - Longitudinal Validation of a Computerized Cognitive Battery (Cognigram) in the Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease
Not yet recruiting NCT05041790 - A Clinical Trial to Evaluate the Efficacy and Safety of Choline Alfoscerate Compared to Placebo in Patients With Degenerative Mild Cognitive Impairment Phase 4
Recruiting NCT04121156 - High Definition Transcranial Direct Current Stimulation (HD-tDCS) in Patients With Mild Cognitive Impairment N/A
Recruiting NCT03605381 - MORbidity PRevalence Estimate In StrokE
Completed NCT02774083 - Cognitive Training Using Feuerstein Instrumental Enrichment N/A
Completed NCT01315639 - New Biomarker for Alzheimer's Disease Diagnostic N/A
Enrolling by invitation NCT06023446 - Can (Optical Coherence Tomography) Pictures of the Retina Detect Alzheimer's Disease at Its Earliest Stages?
Completed NCT04567745 - Automated Retinal Image Analysis System (EyeQuant) for Computation of Vascular Biomarkers Phase 1
Recruiting NCT05579236 - Cortical Disarray Measurement in Mild Cognitive Impairment and Alzheimer's Disease
Completed NCT03583879 - Using Gait Robotics to Improve Symptoms of Parkinson's Disease N/A
Terminated NCT02503501 - Intranasal Glulisine in Amnestic Mild Cognitive Impairment and Probable Mild Alzheimer's Disease Phase 2
Not yet recruiting NCT03740178 - Multiple Dose Trial of MK-4334 in Participants With Alzheimer's Clinical Syndrome (MK-4334-005) Phase 1
Active, not recruiting NCT05204940 - Longitudinal Observational Biomarker Study
Recruiting NCT02663531 - Retinal Neuro-vascular Coupling in Patients With Neurodegenerative Disease N/A
Recruiting NCT06150352 - Sleep Apnea, Neurocognitive Decline and Brain Imaging in Patients With Subjective or Mild Cognitive Impairment
Recruiting NCT03507192 - Effects of Muscle Relaxation on Cognitive Function in Patients With Mild Cognitive Impairment and Early Stage Dementia. N/A